These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 19649992

  • 1. BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis.
    Correale J, Fiol M.
    Curr Opin Mol Ther; 2009 Aug; 11(4):463-70. PubMed ID: 19649992
    [Abstract] [Full Text] [Related]

  • 2. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
    Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H.
    Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
    [Abstract] [Full Text] [Related]

  • 3. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.
    Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, Losy J, Nadj I, Radue EW, Kidd BA, Gianettoni J, Tersini K, Utz PJ, Valone F, Steinman L, BHT-3009 Study Group.
    Ann Neurol; 2008 May; 63(5):611-20. PubMed ID: 18481290
    [Abstract] [Full Text] [Related]

  • 4. DNA-based vaccines: the future of multiple sclerosis therapy?
    Stüve O, Cravens PD, Eagar TN.
    Expert Rev Neurother; 2008 Mar; 8(3):351-60. PubMed ID: 18345967
    [Abstract] [Full Text] [Related]

  • 5. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
    Fontoura P, Garren H, Steinman L.
    Int Rev Immunol; 2005 Mar; 24(5-6):415-46. PubMed ID: 16318989
    [Abstract] [Full Text] [Related]

  • 6. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
    Darlington C.
    Curr Opin Mol Ther; 2007 Aug; 9(4):398-402. PubMed ID: 17694453
    [Abstract] [Full Text] [Related]

  • 7. A DNA vaccine for multiple sclerosis.
    Garren H.
    Expert Opin Biol Ther; 2008 Oct; 8(10):1539-50. PubMed ID: 18774921
    [Abstract] [Full Text] [Related]

  • 8. DNA plasmid vaccination for multiple sclerosis.
    Stüve O, Eagar TN, Frohman EM, Cravens PD.
    Arch Neurol; 2007 Oct; 64(10):1385-6. PubMed ID: 17923622
    [No Abstract] [Full Text] [Related]

  • 9. DNA-based vaccines for multiple sclerosis: current status and future directions.
    Fissolo N, Montalban X, Comabella M.
    Clin Immunol; 2012 Jan; 142(1):76-83. PubMed ID: 21163708
    [Abstract] [Full Text] [Related]

  • 10. A DNA vaccine for the prevention of Ebola virus infection.
    Dery M, Bausch DG.
    Curr Opin Mol Ther; 2008 Jun; 10(3):285-93. PubMed ID: 18535936
    [Abstract] [Full Text] [Related]

  • 11. Human clinical trials of plasmid DNA vaccines.
    Liu MA, Ulmer JB.
    Adv Genet; 2005 Jun; 55():25-40. PubMed ID: 16291211
    [Abstract] [Full Text] [Related]

  • 12. Molecular "negativity" may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS.
    Musse AA, Harauz G.
    Int Rev Neurobiol; 2007 Jun; 79():149-72. PubMed ID: 17531841
    [Abstract] [Full Text] [Related]

  • 13. Inverse vaccination, the opposite of Jenner's concept, for therapy of autoimmunity.
    Steinman L.
    J Intern Med; 2010 May; 267(5):441-51. PubMed ID: 20433574
    [Abstract] [Full Text] [Related]

  • 14. Hydrolysis of myelin basic protein by IgM and IgA antibodies from the sera of patients with multiple sclerosis.
    Polosukhina DI, Buneva VN, Doronin BM, Tyshkevich OB, Boiko AN, Gusev EI, Favorova OO, Nevinsky GA.
    Med Sci Monit; 2005 Aug; 11(8):BR266-72. PubMed ID: 16049372
    [Abstract] [Full Text] [Related]

  • 15. Apoptosis of oligodendrocytes and post-translational modifications of myelin basic protein in multiple sclerosis: possible role for the early stages of multiple sclerosis.
    Artemiadis AK, Anagnostouli MC.
    Eur Neurol; 2010 Aug; 63(2):65-72. PubMed ID: 20068323
    [Abstract] [Full Text] [Related]

  • 16. Antibodies against a class II HLA-peptide complex raised by active immunization of mice with antigen mimicking peptides.
    Dam-Tuxen R, Riise E.
    Scand J Immunol; 2009 Aug; 70(2):93-100. PubMed ID: 19630914
    [Abstract] [Full Text] [Related]

  • 17. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B, Hartung HP.
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [Abstract] [Full Text] [Related]

  • 18. Phosphorylation of U24 from Human Herpes Virus type 6 (HHV-6) and its potential role in mimicking myelin basic protein (MBP) in multiple sclerosis.
    Tait AR, Straus SK.
    FEBS Lett; 2008 Aug 06; 582(18):2685-8. PubMed ID: 18616943
    [Abstract] [Full Text] [Related]

  • 19. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
    Linker RA, Lee DH, Stangel M, Gold R.
    Expert Rev Neurother; 2008 Nov 06; 8(11):1683-90. PubMed ID: 18986239
    [Abstract] [Full Text] [Related]

  • 20. Assuring the quality, safety, and efficacy of DNA vaccines.
    Robertson JS, Griffiths E.
    Mol Biotechnol; 2001 Feb 06; 17(2):143-9. PubMed ID: 11395863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.